{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:12:07Z","timestamp":1792087927018,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1810240"],"award-info":[{"award-number":["W81XWH1810240"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA221705"],"award-info":[{"award-number":["U54 CA221705"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM142606-01"],"award-info":[{"award-number":["GM142606-01"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R21 AR078350-01A1"],"award-info":[{"award-number":["R21 AR078350-01A1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014042","name":"Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cyto.2022.156081","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T20:29:59Z","timestamp":1667248199000},"page":"156081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance"],"prefix":"10.1016","volume":"161","author":[{"given":"Jorge","family":"Canar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Darling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Dadey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2022.156081_b0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cyto.2016.01.010","article-title":"Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer","volume":"89","author":"Ortiz","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-cancerbio-030617-050606","article-title":"Mechanisms of Tumor Cell-Intrinsic Immune Evasion","volume":"2","author":"Spranger","year":"2018","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.cyto.2022.156081_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606456","article-title":"Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways","volume":"11","author":"Mazewski","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0020","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jaci.2022.01.026","article-title":"Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency","volume":"150","author":"Gothe","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1016\/j.cyto.2022.156081_b0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/BJ20140644","article-title":"STAT2\/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1","volume":"466","author":"Blaszczyk","year":"2015","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0030","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1038\/s41467-019-10970-y","article-title":"A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription","volume":"10","author":"Platanitis","year":"2019","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.cyto.2022.156081_b0035","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/emboj.2013.203","article-title":"IFN\u03b2-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage","volume":"32","author":"Cheon","year":"2013","journal-title":"The EMBO Journal"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1073\/pnas.1909879116","article-title":"FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation","volume":"117","author":"Lee","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.cyto.2022.156081_b0045","first-page":"4866","article-title":"Expression profile and prognostic values of STAT family members in non-small cell lung cancer","volume":"11","author":"Yang","year":"2019","journal-title":"Am J Transl Res"},{"issue":"6","key":"10.1016\/j.cyto.2022.156081_b0050","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1016\/j.ygeno.2020.06.032","article-title":"Mining therapeutic and prognostic significance of STATs in renal cell carcinoma with bioinformatics analysis","volume":"112","author":"Zhou","year":"2020","journal-title":"Genomics"},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0055","doi-asserted-by":"crossref","first-page":"e24315","DOI":"10.1002\/jcla.24315","article-title":"Signal transducer and activator of transcription family is a prognostic marker associated with immune infiltration in endometrial cancer","volume":"36","author":"Zhou","year":"2022","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"10.1016\/j.cyto.2022.156081_b0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/jpm12020140","article-title":"High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients","volume":"12","author":"Huang","year":"2022","journal-title":"Journal of Personalized Medicine"},{"issue":"5","key":"10.1016\/j.cyto.2022.156081_b0065","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192319","article-title":"Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy","volume":"217","author":"Gruber","year":"2020","journal-title":"J. Exp. Med."},{"issue":"42","key":"10.1016\/j.cyto.2022.156081_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav7501","article-title":"Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2","volume":"4","author":"Duncan","year":"2019","journal-title":"Sci Immunol"},{"issue":"12","key":"10.1016\/j.cyto.2022.156081_b0075","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers11121943","article-title":"Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications","volume":"11","author":"Aric\u00f2","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cyto.2022.156081_b0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euros.2020.11.003","article-title":"Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not","volume":"22","author":"Hemminki","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"12","key":"10.1016\/j.cyto.2022.156081_b0085","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2174\/092986707780597907","article-title":"Interferon: cellular executioner or white knight?","volume":"14","author":"Maher","year":"2007","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.cyto.2022.156081_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.cyto.2022.156081_b0095","first-page":"2840","article-title":"Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder","volume":"7","author":"Slaton","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cyto.2022.156081_b0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cyto.2018.04.006","article-title":"Tumor inherent interferons: Impact on immune reactivity and immunotherapy","volume":"118","author":"Brockwell","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2022.156081_b0105","doi-asserted-by":"crossref","unstructured":"X. Wang, J.E. Schoenhals, A. Li, D.R. Valdecanas, H. Ye, F. Zang, C. Tang, M. Tang, C.G. Liu, X. Liu, S. Krishnan, J.P. Allison, P. Sharma, P. Hwu, R. Komaki, W.W. Overwijk, D.R. Gomez, J.Y. Chang, S.M. Hahn, M.A. Cortez, J.W. Welsh, Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy, Cancer Res 77(4) (2017) 839-850.","DOI":"10.1158\/0008-5472.CAN-15-3142"},{"issue":"2","key":"10.1016\/j.cyto.2022.156081_b0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","article-title":"Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment","volume":"31","author":"Katlinski","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0115","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.cyto.2022.156081_b0120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.cyto.2022.156081_b0125","doi-asserted-by":"crossref","unstructured":"C. De Angelis, X. Fu, M.L. Cataldo, A. Nardone, R. Pereira, J. Veeraraghavan, S. Nanda, L. Qin, V. Sethunath, T. Wang, S.G. Hilsenbeck, M. Benelli, I. Migliaccio, C. Guarducci, L. Malorni, L.M. Litchfield, J. Liu, J. Donaldson, P. Selenica, D.N. Brown, B. Weigelt, J.S. Reis-Filho, B.H. Park, S.A. Hurvitz, D.J. Slamon, M.F. Rimawi, V.M. Jansen, R. Jeselsohn, C.K. Osborne, R. Schiff, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4\/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer, Clin Cancer Res 27(17) (2021) 4870-4882.","DOI":"10.1158\/1078-0432.CCR-19-4191"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00018-009-0132-1","article-title":"The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells","volume":"67","author":"Pankov\u00e1","year":"2010","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41597-020-0499-2","article-title":"High-throughput transcriptomic and proteomic profiling of mesenchymal-amoeboid transition in 3D collagen","volume":"7","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Sci. Data"},{"issue":"9","key":"10.1016\/j.cyto.2022.156081_b0140","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3390\/cancers12092450","article-title":"Sustained Inflammatory Signalling through Stat1\/Stat2\/IRF9 Is Associated with Amoeboid Phenotype of Melanoma Cells","volume":"12","author":"Gandalovi\u010dov\u00e1","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cyto.2022.156081_b0145","doi-asserted-by":"crossref","first-page":"10622","DOI":"10.1038\/srep10622","article-title":"Tumor invasion optimization by mesenchymal-amoeboid heterogeneity","volume":"5","author":"Hecht","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.cyto.2022.156081_b0150","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jcp.29044","article-title":"Cancer stem cells: A review from origin to therapeutic implications","volume":"235","author":"Atashzar","year":"2020","journal-title":"J Cell Physiol"},{"issue":"52","key":"10.1016\/j.cyto.2022.156081_b0155","doi-asserted-by":"crossref","first-page":"13792","DOI":"10.1073\/pnas.1713728114","article-title":"Interferon-beta represses cancer stem cell properties in triple-negative breast cancer","volume":"114","author":"Doherty","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0160","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cyto.2022.156081_b0165","doi-asserted-by":"crossref","first-page":"8334","DOI":"10.3390\/ijms22158334","article-title":"The Role of the IL-6 Cytokine Family in Epithelial-Mesenchymal Plasticity in Cancer Progression","volume":"22","author":"Abaurrea","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.cyto.2022.156081_b0170","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1073\/pnas.1714102115","article-title":"IRF9 and unphosphorylated STAT2 cooperate with NF-\u03baB to drive IL6 expression","volume":"115","author":"Nan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cyto.2022.156081_b0175","doi-asserted-by":"crossref","unstructured":"A.M. Gamero, M.R. Young, R. Mentor-Marcel, G. Bobe, A.J. Scarzello, J. Wise, N.H. Colburn, STAT2 contributes to promotion of colorectal and skin carcinogenesis, Cancer Prev Res (Phila) 3(4) (2010) 495-504.","DOI":"10.1158\/1940-6207.CAPR-09-0105"},{"issue":"12","key":"10.1016\/j.cyto.2022.156081_b0180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.cyto.2022.156081_b0185","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0190","doi-asserted-by":"crossref","first-page":"1860477","DOI":"10.1080\/2162402X.2020.1860477","article-title":"Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production","volume":"10","author":"Qiu","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4049\/jimmunol.1500152","article-title":"STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation","volume":"197","author":"Xu","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ijc.29004","article-title":"Host STAT2\/type I interferon axis controls tumor growth","volume":"136","author":"Yue","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cyto.2022.156081_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690201","article-title":"Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes","volume":"12","author":"Ardighieri","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156081_b0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.cyto.2022.156081_b0215","doi-asserted-by":"crossref","first-page":"e003521","DOI":"10.1136\/jitc-2021-003521","article-title":"Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma","volume":"9","author":"Reschke","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"issue":"28","key":"10.1016\/j.cyto.2022.156081_b0220","doi-asserted-by":"crossref","first-page":"24978","DOI":"10.18632\/oncotarget.4617","article-title":"Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.cyto.2022.156081_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0230","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"10.1016\/j.cyto.2022.156081_b0235","doi-asserted-by":"crossref","first-page":"e147025","DOI":"10.1172\/JCI147025","article-title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer","volume":"131","author":"He","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cyto.2022.156081_b0240","doi-asserted-by":"crossref","unstructured":"D. Davar, H. Wang, J.M. Chauvin, O. Pagliano, J.J. Fourcade, M. Ka, C. Menna, A. Rose, C. Sander, A.A. Borhani, A. Karunamurthy, A.A. Tarhini, H.A. Tawbi, Q. Zhao, B.H. Moreno, S. Ebbinghaus, N. Ibrahim, J.M. Kirkwood, H.M. Zarour, Phase Ib\/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma, J Clin Oncol 36(35) (2018) Jco1800632.","DOI":"10.1200\/JCO.18.00632"},{"issue":"8","key":"10.1016\/j.cyto.2022.156081_b0245","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0250","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1172\/JCI200318637","article-title":"Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain","volume":"112","author":"Wang","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4049\/jimmunol.179.1.463","article-title":"Stat2-dependent regulation of MHC class II expression","volume":"179","author":"Zhao","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0260","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/1541-7786.MCR-15-0278","article-title":"Sonic Hedgehog Signaling Drives Mitochondrial Fragmentation by Suppressing Mitofusins in Cerebellar Granule Neuron Precursors and Medulloblastoma","volume":"14","author":"Malhotra","year":"2016","journal-title":"Mol Cancer Res"},{"issue":"10","key":"10.1016\/j.cyto.2022.156081_b0265","doi-asserted-by":"crossref","first-page":"e2000117","DOI":"10.1371\/journal.pbio.2000117","article-title":"STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways","volume":"14","author":"Ho","year":"2016","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomarker Res."},{"key":"10.1016\/j.cyto.2022.156081_b0275","doi-asserted-by":"crossref","unstructured":"R.J. Critchley-Thorne, D.L. Simons, N. Yan, A.K. Miyahira, F.M. Dirbas, D.L. Johnson, S.M. Swetter, R.W. Carlson, G.A. Fisher, A. Koong, S. Holmes, P.P. Lee, Impaired interferon signaling is a common immune defect in human cancer, Proceedings of the National Academy of Sciences 106(22) (2009) 9010-9015.","DOI":"10.1073\/pnas.0901329106"},{"issue":"10","key":"10.1016\/j.cyto.2022.156081_b0280","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1541-7786.MCR-17-0180","article-title":"Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer","volume":"15","author":"Walter","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.cyto.2022.156081_b0285","doi-asserted-by":"crossref","first-page":"1758547","DOI":"10.1080\/2162402X.2020.1758547","article-title":"Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer","volume":"9","author":"Walter","year":"2020","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc3700","article-title":"Roles of F-box proteins in cancer","volume":"14","author":"Wang","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cyto.2022.156081_b0295","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.omto.2021.11.019","article-title":"Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus","volume":"24","author":"Goad","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.cyto.2022.156081_b0300","doi-asserted-by":"crossref","unstructured":"R.R. Weichselbaum, H. Ishwaran, T. Yoon, D.S.A. Nuyten, S.W. Baker, N. Khodarev, A.W. Su, A.Y. Shaikh, P. Roach, B. Kreike, B. Roizman, J. Bergh, Y. Pawitan, M.J.v.d. Vijver, A.J. Minn, An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer, Proceedings of the National Academy of Sciences 105(47) (2008) 18490-18495.","DOI":"10.1073\/pnas.0809242105"},{"issue":"47","key":"10.1016\/j.cyto.2022.156081_b0305","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"Weichselbaum","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.cyto.2022.156081_b0310","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1002\/ijc.29161","article-title":"Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs","volume":"136","author":"Kolosenko","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cyto.2022.156081_b0315","article-title":"Increased IRF9\u2013STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis","author":"Wang","year":"2022","journal-title":"J, Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.cyto.2022.156081_b0320","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon\u2013mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J. Exp. Med."},{"issue":"70","key":"10.1016\/j.cyto.2022.156081_b0325","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.21801","article-title":"Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer","volume":"8","author":"Nascimento","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.cyto.2022.156081_b0330","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cac2.12274","article-title":"The Fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells","volume":"42","author":"Wang","year":"2022","journal-title":"Cancer Commun."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622002903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622002903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:47:46Z","timestamp":1760910466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466622002903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":66,"alternative-id":["S1043466622002903"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2022.156081","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2022.156081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156081"}}